Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini Oral - Gynaecological cancers 2

814MO - Phase II study of olaparib (O) plus durvalumab (D) and bevacizumab (B) (MEDIOLA): Initial results in patients (pts) with non-germline BRCA-mutated (non-gBRCAm) platinum sensitive relapsed (PSR) ovarian cancer (OC)

Date

18 Sep 2020

Session

Mini Oral - Gynaecological cancers 2

Topics

Immunotherapy

Tumour Site

Ovarian Cancer

Presenters

Yvette Drew

Citation

Annals of Oncology (2020) 31 (suppl_4): S551-S589. 10.1016/annonc/annonc276

Authors

Y. Drew1, R.T. Penson2, D.M. O'Malley3, J. Kim4, S. Zimmermann5, P. Roxburgh6, J. Sohn7, S.M. Stemmer8, S. Bastian9, M. Ferguson10, B. You11, S. Domchek12, H. Gao13, H. Angell14, K. Meyer15, L. Opincar15, L. Ottesen14, D.O. Koralek16, S. Banerjee17

Author affiliations

  • 1 Medical Oncology, Northern Centre for Cancer Care, Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University, NE2 4HH - Newcastle-upon-Tyne/GB
  • 2 Medical Oncology, Massachusetts General Hospital, 02114 - Boston/US
  • 3 Medical Oncology, The Ohio State University- James Comprehensive Cancer Center, 43210 - Columbus/US
  • 4 Medical Oncology, Seoul National University Hospital, Seoul/KP
  • 5 Medical Oncology, Lausanne University Hospital, University of Lausanne, Lausanne/CH
  • 6 Oncology Department, Beatson West of Scotland Cancer Centre, G12 0YN - Glasgow/GB
  • 7 Medical Oncology, Yonsei Cancer Center, Yonsei University, Sinchon-dong/KP
  • 8 Medical Oncology, Rabin Medical Center-Beilinson Campus, Petach Tikva and Tel-Aviv University, Tel-Aviv/IL
  • 9 Oncology Department, Kantonsspital Graubünden, 7000 - Chur/CH
  • 10 Medical Oncology, NHS Tayside, Dundee/GB
  • 11 Medical Oncology, Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), CITOHL, GINECO, Univ Lyon, Université Claude Bernard Lyon 1, Faculté de medicine Lyon-Sud, 3738 - Lyon/FR
  • 12 Medical Oncology, Basser Center for BRCA, University of Pennsylvania, Philadelphia/US
  • 13 Global Medicines Development, AstraZeneca, Cambridge/GB
  • 14 Oncology R&d, AstraZeneca, Cambridge/GB
  • 15 Global Medicines Development, AstraZeneca, Gaithersburg/US
  • 16 Late Development Oncology, AstraZeneca, Gaithersburg/US
  • 17 Gynaecology Department, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, SW3 6JJ - London/GB
More

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 814MO

Background

Olaparib is a PARP inhibitor approved in first-line and recurrent OC. Results of O+D in gBRCAm PSR OC have been presented. MEDIOLA (NCT02734004) then evaluated combining O+D (doublet cohort) or O+D+B (triplet cohort) in non-gBRCAm PSR OC. Here we present initial results.

Methods

Pts had confirmed non-gBRCAm PSR OC and had progressed after receiving 1–2 prior lines (L) of platinum-based chemotherapy. Pts received O 300 mg bid and D 1.5g IV q4 weeks (w) and B 10 mg/kg q2w (triplet only) until progressive disease. Tumours were assessed by RECIST v1.1 at baseline and q8w. Primary endpoints were safety and 24-w disease control rate (DCR). Secondary endpoints included objective response rate (ORR), median duration of response (mDOR) and progression-free survival (PFS).

Results

From Nov 2018 to Feb 2019, 32 pts (69% 2nd L) enrolled and received O+D; from May 2018 to Jan 2019, 31 (68% 2nd L) enrolled and received O+D+B. At the data cut-off 13 Feb 2020, 22% of O+D and 42% of O+D+B pts remained on treatment. The most common grade ≥3 AEs in O+D were anaemia, lipase increased and neutropenia and anaemia, hypertension, fatigue, lipase increased, and neutropenia in O+D+B. Two (6%) and five (16%) pts discontinued one or more study drug due to an AE in O+D and O+D+B, respectively. Efficacy is summarized in the table. Efficacy in biomarker subgroups, including by presence of genome-wide loss of heterozygosity, will be presented. Table: 814MO

Non-gBRCAm PSR OC Doublet cohort (O+D) n=32 Triplet cohort (O+D+B) n=31
24-w DCR, % 28.1% (90% CI 15.5–43.9) 77.4% (90% CI 61.7–88.9)
Confirmed ORR, % 31.3% (95% CI 16.1–50.0) 77.4% (95% CI 58.9–90.4)
Median confirmed DOR (mo) 6.9 (IQR 5.7–11.1) 11.1 (IQR 9.0–16.4)
Median PFS (mo) 5.5 (95% CI 3.6–7.5) 14.7 (95% CI 10.0–18.1)

CI, confidence interval; IQR, interquartile range.

Conclusions

Combining O+D and O+D+B was well tolerated in pts with non-gBRCAm PSR OC, consistent with the known safety profiles of the single agents. The DCR for the doublet cohort did not meet the prespecified target of 80%. The 95% CI for DCR in the triplet cohort included the prespecified target of 80%. ORR and PFS in the triplet cohort demonstrate promising activity in non-gBRCAm PSR OC, and in this group the ORR and PFS are higher than reported for single-agent PARP or VEGF inhibitors.

Clinical trial identification

NCT02734004.

Editorial acknowledgement

Medical writing assistance was provided by Elin Pyke, MChem, from Mudskipper Business, Ltd, funded by AstraZeneca.

Legal entity responsible for the study

AstraZeneca.

Funding

AstraZeneca.

Disclosure

Y. Drew: Honoraria (self), Honoraria (institution), Advisory/Consultancy: AstraZeneca. R.T. Penson: Honoraria (institution), Advisory/Consultancy: AstraZeneca. D.M. O'Malley: Honoraria (self), Honoraria (institution): AstraZeneca; Honoraria (self), Honoraria (institution): Clovis; Honoraria (self), Honoraria (institution): Tesaro & Immunogen; Honoraria (self): Ambry; Honoraria (self), Honoraria (institution): Janssen/J&J; Honoraria (self), Honoraria (institution): AbbVie; Honoraria (self), Honoraria (institution): Regeneron; Honoraria (self), Honoraria (institution): Amgen; Honoraria (self), Honoraria (institution): Novocure; Honoraria (self), Honoraria (institution): Genentech/Roche; Honoraria (institution): VentiRx; Honoraria (institution): Array Biopharma; Honoraria (institution): EMD Serono; Honoraria (institution): Ergomed; Honoraria (institution): Ajinmoto Inc; Honoraria (institution): Ludwig Cancer Research; Honoraria (institution): Stemcentrx, Inc.; Honoraria (institution): Cerulean Pharma; Honoraria (self), Honoraria (institution): GOG Foundation; Honoraria (institution): Bristol-Myers Squibb; Honoraria (institution): Serono Inc.; Honoraria (institution): Tracon Pharmaceuticals; Honoraria (institution): Yale University; Honoraria (institution): New Mexico Cancer Care Alliance; Honoraria (institution): INC Research, Inc.; Honoraria (institution): inVentiv Health Clinical; Honoraria (institution): Iovance Biotherapeutics, Inc.; Honoraria (institution): PRA International; Honoraria (self): Myriad Genetics, Tarveda; Honoraria (self), Honoraria (institution): Eisai, Agenus, GSK, Merck. S. Zimmermann: Honoraria (self), Non-remunerated activity/ies: Roche; Honoraria (self), Non-remunerated activity/ies: Eli Lilly; Honoraria (self), Non-remunerated activity/ies: Bristol-Myers Squibb; Honoraria (self), Non-remunerated activity/ies: AstraZeneca; Honoraria (self), Non-remunerated activity/ies: MSD; Honoraria (self), Non-remunerated activity/ies: Novartis; Non-remunerated activity/ies: Amgen; Non-remunerated activity/ies: Astellas; Spouse/Financial dependant: Merck KGaA; Non-remunerated activity/ies: Vifor. P. Roxburgh: Honoraria (institution), Advisory/Consultancy: AstraZeneca; Honoraria (self): GlaxoSmithKline; Honoraria (institution): Tesaro. B. You: Advisory/Consultancy, Travel/Accommodation/Expenses: AstraZeneca. S. Domchek: Honoraria (self): AstraZeneca; Honoraria (self): Clovis; Honoraria (self): Bristol-Myers Squibb. H. Gao: Shareholder/Stockholder/Stock options, Full/Part-time employment: AstraZeneca. H. Angell: Shareholder/Stockholder/Stock options, Full/Part-time employment: AstraZeneca. K. Meyer: Research grant/Funding (self), Travel/Accommodation/Expenses, Shareholder/Stockholder/Stock options, Full/Part-time employment: AstraZeneca. L. Opincar: Research grant/Funding (self), Shareholder/Stockholder/Stock options, Full/Part-time employment: AstraZeneca. L. Ottesen: Shareholder/Stockholder/Stock options, Full/Part-time employment: AstraZeneca. D.O. Koralek: Shareholder/Stockholder/Stock options, Full/Part-time employment: AstraZeneca. S. Banerjee: Honoraria (self), Research grant/Funding (institution): AstraZeneca; Honoraria (self): Tesaro; Honoraria (self): Clovis Oncology; Honoraria (self): Merck; Honoraria (self): PharmaMar; Honoraria (self): Roche; Honoraria (self): Seattle Genetics; Honoraria (self): Nucana. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.